AdooQ BioScience is a supplier of biochemicals located in Irvine, CA since 2006. In the past five years, we have been a renowned name engaged in manufacturing and supplying small molecule inhibitors including kinase inhibitors on kinds of signal pathway, such as PI3K, AKT, HDAC, MARP etc.
Company WebsiteTirasemtiv amplifies skeletal muscle response to nerve activation in humans.
More Information Supplier PageTirasemtiv amplifies skeletal muscle response to nerve activation in humans.
More Information Supplier PageTirasemtiv amplifies skeletal muscle response to nerve activation in humans.
More Information Supplier PageTirasemtiv amplifies skeletal muscle response to nerve activation in humans.
More Information Supplier PageTirofiban, Hydrochloride Hydrate is a specific nonpeptide platelet fibrinogen receptor (GPIIb/IIIa) antagonist.
More Information Supplier PageTirofiban, Hydrochloride Hydrate is a specific nonpeptide platelet fibrinogen receptor (GPIIb/IIIa) antagonist.
More Information Supplier PageTirofiban, Hydrochloride Hydrate is a specific nonpeptide platelet fibrinogen receptor (GPIIb/IIIa) antagonist.
More Information Supplier PageTirofiban, Hydrochloride Hydrate is a specific nonpeptide platelet fibrinogen receptor (GPIIb/IIIa) antagonist.
More Information Supplier PageTivozanib (AV-951) is an oral VEGF receptor tyrosine kinase inhibitor that is designed to inhibit all three VEGF receptors.
More Information Supplier PageTivozanib (AV-951) is an oral VEGF receptor tyrosine kinase inhibitor that is designed to inhibit all three VEGF receptors.
More Information Supplier PageTivozanib (AV-951) is an oral VEGF receptor tyrosine kinase inhibitor that is designed to inhibit all three VEGF receptors.
More Information Supplier PageTivozanib (AV-951) is an oral VEGF receptor tyrosine kinase inhibitor that is designed to inhibit all three VEGF receptors.
More Information Supplier PageTivozanib (AV-951) is an oral VEGF receptor tyrosine kinase inhibitor that is designed to inhibit all three VEGF receptors.
More Information Supplier PageTLQP 21, VGF-derived peptide; spans residues 556-576 of the precursor sequence.
More Information Supplier PageTMC353121 is a potent RSV fusion inhibitor in vitro, Antiviral agents and a novel candidate for RSV disease treatment.
More Information Supplier PageTMC353121 is a potent RSV fusion inhibitor in vitro, Antiviral agents and a novel candidate for RSV disease treatment.
More Information Supplier PageTMC353121 is a potent RSV fusion inhibitor in vitro, Antiviral agents and a novel candidate for RSV disease treatment.
More Information Supplier PageTMC353121 is a potent RSV fusion inhibitor in vitro, Antiviral agents and a novel candidate for RSV disease treatment.
More Information Supplier PageMCB has been shown to inhibit both casein kinase 2 (CK2) and extracellular-signal-regulated kinase 8 (ERK8/MAPK15) (IC50 = 0.50 ??M for both CK2 and ERK8).
More Information Supplier PageMCB has been shown to inhibit both casein kinase 2 (CK2) and extracellular-signal-regulated kinase 8 (ERK8/MAPK15) (IC50 = 0.50 ??M for both CK2 and ERK8).
More Information Supplier PageMCB has been shown to inhibit both casein kinase 2 (CK2) and extracellular-signal-regulated kinase 8 (ERK8/MAPK15) (IC50 = 0.50 ??M for both CK2 and ERK8).
More Information Supplier PageTMP 269 is a potent, selective class IIa HDAC inhibitor with IC50 of 157 nM, 97 nM, 43 nM and 23 nM for HDAC4, HDAC5, HDAC7 and HDAC9, respectively.
More Information Supplier PageTMP 269 is a potent, selective class IIa HDAC inhibitor with IC50 of 157 nM, 97 nM, 43 nM and 23 nM for HDAC4, HDAC5, HDAC7 and HDAC9, respectively.
More Information Supplier PageTMP 269 is a potent, selective class IIa HDAC inhibitor with IC50 of 157 nM, 97 nM, 43 nM and 23 nM for HDAC4, HDAC5, HDAC7 and HDAC9, respectively.
More Information Supplier PageTMP 269 is a potent, selective class IIa HDAC inhibitor with IC50 of 157 nM, 97 nM, 43 nM and 23 nM for HDAC4, HDAC5, HDAC7 and HDAC9, respectively.
More Information Supplier PageTMPA is a novel small molecule that binds to orphan Nuclear Receptor Nur77 with high affinity (Kd = 1.45 ?? 0.35 ??M), and interferes with the Nur77-LKB1 interaction.
More Information Supplier PageTMPA is a novel small molecule that binds to orphan Nuclear Receptor Nur77 with high affinity (Kd = 1.45 ?? 0.35 ??M), and interferes with the Nur77-LKB1 interaction.
More Information Supplier PageTMPA is a novel small molecule that binds to orphan Nuclear Receptor Nur77 with high affinity (Kd = 1.45 ?? 0.35 ??M), and interferes with the Nur77-LKB1 interaction.
More Information Supplier PageTMPA is a novel small molecule that binds to orphan Nuclear Receptor Nur77 with high affinity (Kd = 1.45 ?? 0.35 ??M), and interferes with the Nur77-LKB1 interaction.
More Information Supplier PageTMS is a potent, selective and competitive inhibitor of cytochrome P450 1B1, an enzyme overexpressed in certain tumors (IC50= 6 nM). 5N/A- and 520-fold selective over P450 1A1 and 1A2 respectively.
More Information Supplier PageTMS is a potent, selective and competitive inhibitor of cytochrome P450 1B1, an enzyme overexpressed in certain tumors (IC50= 6 nM). 5N/A- and 520-fold selective over P450 1A1 and 1A2 respectively.
More Information Supplier PageTMS is a potent, selective and competitive inhibitor of cytochrome P450 1B1, an enzyme overexpressed in certain tumors (IC50= 6 nM). 5N/A- and 520-fold selective over P450 1A1 and 1A2 respectively.
More Information Supplier PageTMS is a potent, selective and competitive inhibitor of cytochrome P450 1B1, an enzyme overexpressed in certain tumors (IC50= 6 nM). 5N/A- and 520-fold selective over P450 1A1 and 1A2 respectively.
More Information Supplier PageTNP 470 is an analog of Fumagillin that displays potent antiangiogenic activity in vitro. Shown to inhibit MetAP-2 (methionine aminopeptidase type II ).
More Information Supplier PageTNP 470 is an analog of Fumagillin that displays potent antiangiogenic activity in vitro. Shown to inhibit MetAP-2 (methionine aminopeptidase type II ).
More Information Supplier PageTNP 470 is an analog of Fumagillin that displays potent antiangiogenic activity in vitro. Shown to inhibit MetAP-2 (methionine aminopeptidase type II ).
More Information Supplier PageToceranib is a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFR??.
More Information Supplier PageToceranib is a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFR??.
More Information Supplier PageToceranib is a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFR??.
More Information Supplier PageToceranib is a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFR??.
More Information Supplier PageToceranib phosphate is a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFR??.
More Information Supplier PageToceranib phosphate is a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFR??.
More Information Supplier PageToceranib phosphate is a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFR??.
More Information Supplier PageTofogliflozin is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney.
More Information Supplier PageTofogliflozin is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney.
More Information Supplier PageTofogliflozin is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney.
More Information Supplier PageTofogliflozin is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney.
More Information Supplier Page
